Kernekoncepter
Oral psoriasis treatments are evolving, offering new options for patients with psoriasis.
Resumé
The content discusses oral psoriasis treatments in a podcast format featuring Dr. Steve Feldman and guest Lakshi Aldridge, a dermatology nurse practitioner. The conversation covers the role of nurse practitioners in managing psoriasis, the eligibility criteria for oral treatments, and specific considerations for various oral agents. The discussion delves into traditional oral agents like methotrexate, cyclosporine, and acitretin, as well as newer options such as TYK2 and PDE4 inhibitors. Insights are shared on the efficacy, safety profiles, and considerations for each oral treatment. The conversation also touches on the evolving landscape of psoriasis management, emphasizing the importance of a team-based approach and the availability of oral treatments for patients who may be hesitant to try biologics.
Highlights:
Role of nurse practitioners in dermatology care
Evolution of psoriasis treatment options
Considerations for selecting oral agents
Efficacy and safety profiles of different oral treatments
Importance of patient-specific treatment approaches
Statistik
"We have three dermatology nurse practitioner fellowship training programs that are 1-year long."
"Most nurse practitioners gained their education and training in formal training programs."
"TYK2 (tyrosine kinase 2) inhibitor that has come along and the PDE4 (phosphodiesterase-4) inhibitor."
Citater
"The most successful management of any dermatology patient — especially those with complex, chronic cutaneous disorders — is best managed by a derm team."
"The patient sitting in front of you has specific needs."
"Apremilast is a safe choice that's quite convenient."